The proposed mechanism is supported by the report of no significant differences in the frequency of TGF-β+Tregs between alopecia areata patients and healthy controls, although the cell-to-cell contact and CD39 mediated activity of Tregs are impaired (109). The gene discussed is TGFB1; the disease is alopecia areata.